Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Beclometasone oral - Soligenix

Drug Profile

Beclometasone oral - Soligenix

Alternative Names: BDP; DOR 201; DOR 202; DOR 203; Oral BDP - Soligenix/Sigma-Tau; Oral beclomethasone 17,21-dipropionate; orBec; OrbeShield; SGX 201; SGX 202; SGX 203

Latest Information Update: 04 Dec 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Enteron Pharmaceuticals
  • Developer Fred Hutchinson Cancer Research Center; National Institutes of Health (USA); Soligenix
  • Class Antiallergics; Antiasthmatics; Chlorinated steroids; Corticosteroids; Pregnadienetriols; Small molecules; Vascular disorder therapies
  • Mechanism of Action Immunosuppressants; Steroid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Crohn's disease; Graft-versus-host disease; Acute radiation syndrome
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase I/II Radiation injuries
  • Phase I Acute radiation syndrome; Crohn's disease
  • Discontinued Graft-versus-host disease

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 04 Dec 2017 Beclometasone oral is still in phase I trials for Crohn's disease in USA
  • 04 Dec 2017 Phase-I clinical trials in Acute radiation syndrome in USA (PO) (Soligenix pipeline, December 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top